# Correction to “Trametinib Overcomes KRAS ‐G12V–Induced Osimertinib Resistance in a Leptomeningeal Carcinomatosis Model of EGFR ‐Mutant Lung Cancer”

PMC · DOI: 10.1111/cas.70278 · Cancer Science · 2025-11-24

## Full-text entities

- **Genes:** KRAS (KRAS proto-oncogene, GTPase) [NCBI Gene 3845] {aka 'C-K-RAS, C-K-RAS, CFC2, K-RAS2A, K-RAS2B, K-RAS4A}, EGFR (epidermal growth factor receptor) [NCBI Gene 1956] {aka ERBB, ERBB1, ERRP, HER1, NISBD2, NNCIS}
- **Diseases:** Lung Cancer (MESH:D008175), Leptomeningeal Carcinomatosis (MESH:D055756)
- **Chemicals:** Osimertinib (MESH:C000596361), Trametinib (MESH:C560077)
- **Mutations:** G12V

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12861087/full.md

## Figures

1 figure with captions in the complete paper: https://tomesphere.com/paper/PMC12861087/full.md

---
Source: https://tomesphere.com/paper/PMC12861087